Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia
Abstract High‐throughput omics have proven invaluable in studying human disease, and yet day‐to‐day clinical practice still relies on physiological, non‐omic markers. The metabolic syndrome, for example, is diagnosed and monitored by blood and urine indices such as blood cholesterol levels. Neverthe...
Main Authors: | Allon Wagner, Noa Cohen, Thomas Kelder, Uri Amit, Elad Liebman, David M Steinberg, Marijana Radonjic, Eytan Ruppin |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2015-03-01
|
Series: | Molecular Systems Biology |
Subjects: | |
Online Access: | https://doi.org/10.15252/msb.20145486 |
Similar Items
-
Methodology for a reverse engineering process chain with focus on customized segmentation and iterative closest point algorithms
by: Stephan Mönchinger, et al.
Published: (2022-01-01) -
PREDICT: a method for inferring novel drug indications with application to personalized medicine
by: Assaf Gottlieb, et al.
Published: (2011-06-01) -
The Regulation of Reverse Cholesterol Transport and Cellular Cholesterol Homeostasis by MicroRNAs
by: Diana M. DiMarco, et al.
Published: (2015-07-01) -
Some Aspects and Convergence of Human and Veterinary Drug Repositioning
by: Patrik Mag, et al.
Published: (2024-09-01) -
Drug repurposing of clinically-approved drugs to target epithelial-mesenchymal transition using in silico analysis
by: Ong, Chun Hao
Published: (2021)